NO330523B1 - Kombinasjoner av vasobeskyttende agenser og formuleringer inneholdende dem og anvendelse derav - Google Patents
Kombinasjoner av vasobeskyttende agenser og formuleringer inneholdende dem og anvendelse derav Download PDFInfo
- Publication number
- NO330523B1 NO330523B1 NO20056162A NO20056162A NO330523B1 NO 330523 B1 NO330523 B1 NO 330523B1 NO 20056162 A NO20056162 A NO 20056162A NO 20056162 A NO20056162 A NO 20056162A NO 330523 B1 NO330523 B1 NO 330523B1
- Authority
- NO
- Norway
- Prior art keywords
- compositions according
- tocotrienol
- vegetable oil
- lycopene
- polycosanols
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- 230000002666 vasoprotective effect Effects 0.000 title abstract description 5
- 238000009472 formulation Methods 0.000 title description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 10
- 239000008158 vegetable oil Substances 0.000 claims abstract description 10
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 9
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 9
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 9
- 229960004999 lycopene Drugs 0.000 claims abstract description 9
- 235000012661 lycopene Nutrition 0.000 claims abstract description 9
- 239000001751 lycopene Substances 0.000 claims abstract description 9
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 9
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 5
- 229930003802 tocotrienol Natural products 0.000 claims description 9
- 239000011731 tocotrienol Substances 0.000 claims description 9
- 235000019148 tocotrienols Nutrition 0.000 claims description 9
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 2
- 241000157280 Aesculus hippocastanum Species 0.000 claims description 2
- 240000007817 Olea europaea Species 0.000 claims description 2
- 235000002725 Olea europaea Nutrition 0.000 claims description 2
- 241000219295 Portulaca Species 0.000 claims description 2
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 2
- 241001312569 Ribes nigrum Species 0.000 claims description 2
- 235000006468 Thea sinensis Nutrition 0.000 claims description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical class OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 2
- 229940114124 ferulic acid Drugs 0.000 claims description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 2
- 235000001785 ferulic acid Nutrition 0.000 claims description 2
- 235000010181 horse chestnut Nutrition 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009498 luteolin Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 2
- 244000052707 Camellia sinensis Species 0.000 claims 1
- 230000000871 hypocholesterolemic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000003966 vascular damage Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- -1 aliphatic alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Kombinasjoner av vasobeskyttende agenser nyttige for forebyggingen og behandlingen av vaskulære skader påført av et overskudd av plasmalipider omfattende policosanoler, tocotriender og/eller lycopen, procyanidole oligomerer og vegetabilsk olje rik på umettede fettsyrer.
Description
Den foreliggende oppfinnelse vedrører kombinasjoner av vasobeskyttende agenser nyttige for forebyggingen og behandlingen av vaskulære skader forårsaket av et overskudd av plasmalipider. Den foreliggende oppfinnelsen fremviser farmasøytis-ke, dietetiske eller næringssammensetninger samt anvendelse derav som angitt i krav 1-8.
Kombinasjonene ifølge oppfinnelsen reduserer blodkolesterol og triglyceridnivåer mens de beskytter den vaskulære veggen mot skadene forårsaket av overproduk-sjon av frie radikaler og kolesteroloksidiserte former, og styrker således veggen.
Den foreliggende oppfinnelse vedrører kombinasjoner av vasobeskyttende agenser og sammensetninger omfattende nevnte kombinasjoner.
Sykdommen arteriosklerose er et svært kompleks fenomen, ikke bare forbundet med lipidtilstander, derfor har enhver synergetisk handling som angår vaskulær beskyttelse og reduksjon av overproduksjonen frie radikaler hatt stor terapeutisk interesse. Kronisk degenerative lidelser så som kardiovaskulære sykdommer, har ikke én enkel opprinnelse. Høye trigycerid- og kolesterolnivåer, ledsaget av endre-de forhold av lipoproteinfraksjonene, så vel som hypertensjon, forårsaker utvilsomt markerte vaskulære skader med ufordelaktige prognoser. Det er derfor behov for å senke blodkolesterol- og triglyceridnivåer, mens arterieveggene styrkes og beskyt-tes.
Det er nå blitt funnet at dette målet fordelaktig kan oppnås ved å kombinere vasobeskyttende agenser med ulike handlingsmekanismer.
Oppfinnelsen vedrører spesielt farmasøytiske, dietetiske eller næringssammensetninger omfattende: - ett eller flere polycosanoler eller estere derav, enten ublandet eller som ekstrakter;
- tocotrienol og/eller lycopen, fortrinnsvis tocotrienol:
- én eller flere procyanidol oligomerer valgfritt kompleksert med fosfolipider;
og
- en vegetabilsk olje rik på©-3,©-6 umettede fettsyrer.
Hypokolesteroliseringen eller mer generelt anti-arteriosklerotisk aktivitet av hver enkelt komponent i kombinasjonen er kjent, men bare gjennom den kombinerte anvendelsen derav kan det oppnås spesielt bemerkelsesverdig preventive eller te-rapeutiske effekter.
Anvendelsen og fremstillingen av procyanidol oligomerer kompleksert med fosfolipider som anti-ateriosklerotiske agenser er beskrevet i WO 99/29331.
Polycosanoler, så vel som©-3,©-6 umettede fettsyrer, har blitt gjenstand for un-dersøkelser i fagfeltene kardiologi og kardiovaskulære sykdommer i noen tid (hen-holdsvis IntJ Clin Pharm Res 1994;14:27-33 og Ann. Intern. Med. 1999;130:554-62) mens tocotrienol og lycopen, hvilke hører til karotenoidfamilien, har blitt omfattende undersøkt som agenser i stand til å forhindre lipoperoksidasjon og dannelse av frie radikaler, og også som kjemo-forhindrende agenser { Clin. Biochem 1999;32:309-19).
Fra WO 03/103632 Al er det kjent sammensetninger omfattende polycosanoler. Det er angitt at sammensetningen anvendes for behandling av hyperkolesterolemi, hypertriglyseridemi, koronar hjertesykdom, hjerte/kar lidelser og perifer vaskulær sykdom. Det er videre angitt at sammensetningen kan omfatte andre kolesterol-senkende forbindelser.
Fra WO 01/26486 Al er det kjent dietiske eller næringssammensetninger omfattende lycopen og procyanidol oligomerer. Sammensetningene brukes til å forebyg-ge hjerte- og karsykdommer.
Fra US 6605296 Bl er det kjent sammensetninger som har fordelaktige fysiologiske effekter, spesielt med hensyn til hjerte/kar sykdommer. Sammensetningen kan omfatte blant annet lycopen og vegetabilske oljer.
Fra WO 99/29331 Al er det angitt at ekstrakter fra Vitis vinifera er kjent og brukt i behandling av kardiovaskulære lidelser.
Polycosanoler anvendt ifølge oppfinnelsen er rette, langkjedede alifatiske alkoholer, typisk rette alkoholer med 24 til 30 karbonatomer, som kan skaffes ved saponifise-ring av vokser fra vegetabilske materialer så som oliven, hvete, ris, sukkerrør og andre kilder. Disse forbindelser kan anvendes enten i den frie form eller esterifisert med ferulsyre eller andre cinnamater på ulike måter substituert ved fenyldelen, så som p-N02/p-OH og m-CI-cinnamater.
Procyanidololigomerene for anvendelse ifølge oppfinnelsen kan skaffes fra Vitis vinifera, Camellia sinensis, Aesculus hippocastanum, Olea europea.
Den vegetabilske oljen er fortrinnsvis valgt fra Enothera biennis, Ribes nigrum eller Portulaca o/eracea-oljer, mer foretrukket Enothera biennis- o\) e. De©-3,©-6-umettede fettsyrene til stede i nevnte oljer kan valgfritt transformeres til de kor-responderende alkylestere, spesielt de tilsvarende etylestere, ved transesterifise-ring, for eksempel ved å behandle oljen med etanol og H2S04i nærvær av benzen for å fjerne vann azeotropisk.
Sammensetningene ifølge oppfinnelsen kan ytterligere inneholde luteolin per se eller i form av 7,3',4'-hydroksyetylderivater.
Formuleringene ifølge oppfinnelsen kan inneholde 5 til 30 mg, fortrinnsvis 15 mg, polycosanoler; 1 til 50 mg, fortrinnsvis 8 mg, tocotrienol eller lycopen; 30 til 200 mg proantocyanidiner eller 100 til 320 mg proantocyanidiner kompleksert med fosfolipider og 150 til 300 mg vegetabilske oljer per enhet doseringsform.
20 pasienter som lider av hovedsakelig hyperlipidemi med carotid plaque ble be-handlet med en formulering ifølge oppfinnelsen med den følgende sammensetning:
Etter to måneders behandling med to kapsler/dag, viste pasientene normaliserte lipidparametre og forbedret plaque-tilstand, som påvist ved EcoDoppler.
De følgende eksempler illustrerer oppfinnelsen i større detalj:
Eksempel I Eksempel II
Eksempel III Eksempel IV
Eksempel V
Claims (8)
1. Farmasøytiske, dietetiske eller næringssammensetninger,karakterisert vedat den omfatter: - én eller flere polycosanoler eller estere derav, enten rene eller som ekstrakter; - tocotrienol og/eller lycopen, fortrinnsvis tocotrienol; - én eller flere procyanidol oligomerer valgfritt kompleksert med fosfolipider; og - vegetabilsk olje rik på©-3,©-6 umettede fettsyrer.
2. Sammensetninger ifølge krav 1,
karakterisert vedat den vegetabilske oljen er valgt fra Enothera biennis, Ribes nigrum eller Portulaca o/eracea-olje.
3. Sammensetninger ifølge krav 2,
karakterisert vedat den vegetabilske olje er enothera biennis- o\] e.
4. Sammensetninger ifølge ethvert av kravene 1-3,
karakterisert vedat den ytterligere inneholder luteolin enten per se eller i form av 7,3',4'-hydroksyetylderivater.
5. Sammensetninger ifølge ethvert av kravene 1-4,
karakterisert vedat polycosanoler er esterifisert med ferulsyre eller andre ulikt substituerte cinnamater.
6. Sammensetninger ifølge ethvert av kravene 1-5,
karakterisert vedat procyandiol oligomerer utvinnes fra Vitis vinifera, Camellia sinensis, Aesculus hippocastanum, Olea europea.
7. Sammensetninger ifølge ethvert av kravene 1-6,
karakterisert vedat den omfatter 5 til 30 mg polycocsanoler, 1 til 50 mg tocotrienol eller lycopen, 100 til 320 mg proantocyanidiner kompleksert med fosfolipider, 150 til 300 mg vegetabilsk olje, per enhet doseringsform.
8. Anvendelse av en kombinasjon av: - én eller flere polycosanoler, i sin frie eller esterifiserte form, enten ublandet eller ekstrakter inneholdende dem; - tocotrienol og/eller lycopen, fortrinnsvis tocotrienol; - ett eller flere procyandiol oligomerer valgfritt kompleksert med fosfolipider; - en vegetabilsk olje rik på ©-3, ©-6 umettede fettsyrer
for fremstillingen av hypokolesterolemiserende og/eller anti-aterosklerotiske, dietetiske eller næringssammensetninger.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001313A ITMI20031313A1 (it) | 2003-06-27 | 2003-06-27 | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
| PCT/EP2004/006507 WO2005000041A1 (en) | 2003-06-27 | 2004-06-17 | Combinations of vasoprotective agents and formulations containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20056162L NO20056162L (no) | 2005-12-23 |
| NO330523B1 true NO330523B1 (no) | 2011-05-09 |
Family
ID=30131309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20056162A NO330523B1 (no) | 2003-06-27 | 2005-12-23 | Kombinasjoner av vasobeskyttende agenser og formuleringer inneholdende dem og anvendelse derav |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20090036520A1 (no) |
| EP (1) | EP1638417B1 (no) |
| JP (1) | JP4960087B2 (no) |
| KR (1) | KR101165934B1 (no) |
| CN (1) | CN100475061C (no) |
| AU (1) | AU2004251009B2 (no) |
| BR (1) | BRPI0411811B1 (no) |
| CA (1) | CA2530660C (no) |
| DK (1) | DK1638417T3 (no) |
| ES (1) | ES2704633T3 (no) |
| HK (1) | HK1090519A1 (no) |
| HU (1) | HUE042048T2 (no) |
| IT (1) | ITMI20031313A1 (no) |
| MX (1) | MXPA05013625A (no) |
| NO (1) | NO330523B1 (no) |
| NZ (1) | NZ544399A (no) |
| PL (1) | PL1638417T3 (no) |
| PT (1) | PT1638417T (no) |
| RU (2) | RU2361430C2 (no) |
| SI (1) | SI1638417T1 (no) |
| TR (1) | TR201900241T4 (no) |
| WO (1) | WO2005000041A1 (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202541B2 (en) | 2006-02-07 | 2012-06-19 | U.S. Nutraceuticals, LLC | Dietary supplement composition for blood lipid health |
| US8017153B2 (en) | 2006-02-07 | 2011-09-13 | U.S. Nutraceuticals, LLC | Dietary supplement composition for blood lipid health |
| JP4469406B1 (ja) * | 2009-06-30 | 2010-05-26 | 株式会社ファンケル | 血中コレステロール低下剤 |
| JP4469407B1 (ja) * | 2009-06-30 | 2010-05-26 | 株式会社ファンケル | 血中中性脂肪低下剤 |
| KR101294970B1 (ko) * | 2011-06-30 | 2013-08-09 | 고려대학교 산학협력단 | 폴리코사놀 에스터, 이의 제조 방법 및 이를 포함하는 첨가제 |
| RU2631600C2 (ru) * | 2013-03-15 | 2017-09-25 | Наноркс, Инк. | Метадихол® - жидкие и гелевые нанолекарственные препараты |
| IT201900020808A1 (it) * | 2019-11-11 | 2021-05-11 | Neilos S R L | Composizione per la riduzione del rischio cardiovascolare |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1265312B1 (it) * | 1993-12-21 | 1996-10-31 | Indena Spa | Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di |
| JP3142245B2 (ja) * | 1996-06-28 | 2001-03-07 | 株式会社資生堂 | 皮膚外用剤 |
| IT1283143B1 (it) * | 1996-07-12 | 1998-04-07 | Indena Spa | Metodo di estrazione del licopene ed estratti che lo contengono |
| JP2001511153A (ja) * | 1997-02-04 | 2001-08-07 | ブイ． コスバブ，ジョン | 血管変性性疾患の予防および処置のための組成物および方法 |
| US5846569A (en) * | 1997-06-20 | 1998-12-08 | Creative Labs, Inc. | Colostrum supplement |
| US6126943A (en) * | 1997-09-02 | 2000-10-03 | The Ricex Company | Method for treating hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| IT1296920B1 (it) * | 1997-12-04 | 1999-08-03 | Indena Spa | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
| AT407821B (de) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | Mittel auf der basis von naturstoffen |
| KR20000019717A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 루틴 및 쿼세틴을 포함하는 고지혈증, 동맥경화증 및 간 질환의예방 및 치료용 조성물 |
| FR2792831B1 (fr) * | 1999-04-28 | 2001-08-03 | Bionatec Sarl | Composition a destination cosmetique et/ou dietetique comprenant un melange de lycopene et d'extrait de feuille d'olivier |
| KR100319397B1 (ko) | 1999-07-12 | 2002-01-05 | 남 승 우 | 천연식물소재 추출물을 이용한 항혈전 및 고지혈증 억제 조성물 |
| US6667064B2 (en) * | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
| US20020120001A1 (en) * | 2000-10-13 | 2002-08-29 | Ashni Naturaceuticals, Inc. | Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect |
| IT1320180B1 (it) * | 2000-12-29 | 2003-11-26 | Hunza Di Marazzita Maria Carme | Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e |
-
2003
- 2003-06-27 IT IT001313A patent/ITMI20031313A1/it unknown
-
2004
- 2004-06-17 PT PT04739969T patent/PT1638417T/pt unknown
- 2004-06-17 PL PL04739969T patent/PL1638417T3/pl unknown
- 2004-06-17 CA CA2530660A patent/CA2530660C/en not_active Expired - Fee Related
- 2004-06-17 ES ES04739969T patent/ES2704633T3/es not_active Expired - Lifetime
- 2004-06-17 SI SI200432457T patent/SI1638417T1/sl unknown
- 2004-06-17 WO PCT/EP2004/006507 patent/WO2005000041A1/en active Application Filing
- 2004-06-17 BR BRPI0411811-1A patent/BRPI0411811B1/pt not_active IP Right Cessation
- 2004-06-17 MX MXPA05013625A patent/MXPA05013625A/es active IP Right Grant
- 2004-06-17 TR TR2019/00241T patent/TR201900241T4/tr unknown
- 2004-06-17 EP EP04739969.6A patent/EP1638417B1/en not_active Expired - Lifetime
- 2004-06-17 HU HUE04739969A patent/HUE042048T2/hu unknown
- 2004-06-17 DK DK04739969.6T patent/DK1638417T3/en active
- 2004-06-17 RU RU2005140574/13A patent/RU2361430C2/ru not_active IP Right Cessation
- 2004-06-17 JP JP2006515963A patent/JP4960087B2/ja not_active Expired - Lifetime
- 2004-06-17 NZ NZ544399A patent/NZ544399A/en unknown
- 2004-06-17 CN CNB2004800177716A patent/CN100475061C/zh not_active Expired - Fee Related
- 2004-06-17 US US10/562,214 patent/US20090036520A1/en not_active Abandoned
- 2004-06-17 KR KR1020057024537A patent/KR101165934B1/ko active IP Right Grant
- 2004-06-17 AU AU2004251009A patent/AU2004251009B2/en not_active Ceased
-
2005
- 2005-12-23 NO NO20056162A patent/NO330523B1/no not_active IP Right Cessation
-
2006
- 2006-10-17 HK HK06111347.1A patent/HK1090519A1/xx not_active IP Right Cessation
-
2009
- 2009-03-12 RU RU2009109089/13A patent/RU2489907C2/ru not_active IP Right Cessation
-
2010
- 2010-03-10 US US12/721,015 patent/US20100160427A1/en not_active Abandoned
-
2011
- 2011-02-24 US US13/033,826 patent/US8206759B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carvajal-Zarrabal et al. | The consumption of Hibiscus sabdariffa dried calyx ethanolic extract reduced lipid profile in rats | |
| Ahmad et al. | Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats | |
| AU2009200897B2 (en) | Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides | |
| US8507466B2 (en) | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | |
| US8772270B2 (en) | Treatment methods requiring phyto-ingredients | |
| NO330523B1 (no) | Kombinasjoner av vasobeskyttende agenser og formuleringer inneholdende dem og anvendelse derav | |
| Ramadan et al. | Apricot and pumpkin oils reduce plasma cholesterol and triacylglycerol concentrations in rats fed a high-fat diet | |
| US20060198906A1 (en) | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease | |
| EP2675442A1 (en) | Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events | |
| Gupta et al. | Cocunut oil-A novel approach in health promotion and disease prevention | |
| JPH05139966A (ja) | 月経困難症予防または治療剤と月経困難症予防機能性食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |